SK

Sumeela Kasu

Active Director Director DIN 09571540
DIN 09571540 First appointment Jun 2022 Primary industry General Business
View timeline Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Past companies 0 historical roles
Total affiliations 1 Since Jun 2022
Shareholding value Locked Premium profile

About Sumeela Kasu

Sumeela Kasu has 4 years in corporate governance. Holds Director role. Currently with 1 company, including Concord Drugs Limited. Engaged in General Business. Contributes to corporate operations.

DIN 09571540
Primary Designation Director
First Appointment 01 Jun 2022
Oldest Company Age 31 yrs

Current companies

Company Designation Appointment Founded Status
Concord Drugs Limited L24230TG1995PLC020093
Director 01 Jun 2022 1995 Active

Previous companies

No previous companies available.

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Concord Drugs Limited
Premium access

Shareholding and investment profile for Sumeela Kasu

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sumeela Kasu

Sumeela Kasu has 4 years in corporate governance. Holds Director role. Currently with 1 company, including Concord Drugs Limited. Engaged in General Business. Contributes to corporate operations.

Sumeela Kasu is associated with 1 company as Director.

Sumeela Kasu has expertise in General Business.

Sumeela Kasu has 4 years in corporate governance.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available